CanSino Biologics Inc
688185
Company Profile
Business description
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.
Contact
185 South Avenue
401-420, 4th Floor, Biomedical Park
TEDA West District
Tianjin
CHNT: +86 4009222099
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,105
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,816.40 | 58.90 | -0.66% |
CAC 40 | 7,722.09 | 44.12 | -0.57% |
DAX 40 | 24,009.38 | 50.91 | -0.21% |
Dow JONES (US) | 44,254.78 | 231.49 | 0.53% |
FTSE 100 | 8,926.55 | 11.77 | -0.13% |
HKSE | 24,517.76 | 72.36 | -0.29% |
NASDAQ | 20,730.49 | 52.69 | 0.25% |
Nikkei 225 | 39,663.40 | 14.62 | -0.04% |
NZX 50 Index | 12,754.59 | 64.96 | 0.51% |
S&P 500 | 6,263.70 | 19.94 | 0.32% |
S&P/ASX 200 | 8,561.80 | 68.50 | -0.79% |
SSE Composite Index | 3,503.78 | 1.22 | -0.03% |